These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 21744241)

  • 1. Are symptomatic guidelines for chemotherapy appropriate to ER-positive screen-detected breast cancer (SDBC)?
    Bundred NJ; Prasad R; Morris J; Knox WF; Byrne G; Cheung S; Wilson M; Lawrence G
    Breast Cancer Res Treat; 2013 Apr; 138(2):359-68. PubMed ID: 21744241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative study of risk factors and prognostic features between symptomatic and screen detected breast cancer.
    Burke JP; Power C; Gorey TF; Flanagan F; Kerin MJ; Kell MR
    Eur J Surg Oncol; 2008 Feb; 34(2):149-53. PubMed ID: 17498912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High estrogen receptor expression in early breast cancer: chemotherapy needed to improve RFS?
    Regierer AC; Wolters R; Kurzeder C; Wöckel A; Novopashenny I; Possinger K; Wischnewsky MB; Kreienberg R
    Breast Cancer Res Treat; 2011 Jul; 128(1):273-81. PubMed ID: 21210206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
    J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Do screen-detected breast cancers have positive margins less often than clinically detected breast cancers?
    de Munck L; Siesling S; Bart J; Menke-Pluijmers MB; Otter R; Willemse PH
    Eur J Cancer Prev; 2013 Sep; 22(5):398-403. PubMed ID: 23492953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
    Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
    Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Qualitative assessment of the progesterone receptor and HER2 improves the Nottingham Prognostic Index up to 5 years after breast cancer diagnosis.
    Van Belle V; Van Calster B; Brouckaert O; Vanden Bempt I; Pintens S; Harvey V; Murray P; Naume B; Wiedswang G; Paridaens R; Moerman P; Amant F; Leunen K; Smeets A; Drijkoningen M; Wildiers H; Christiaens MR; Vergote I; Van Huffel S; Neven P
    J Clin Oncol; 2010 Sep; 28(27):4129-34. PubMed ID: 20713855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Akt2 expression is associated with good long-term prognosis in oestrogen receptor positive breast cancer.
    Fohlin H; Pérez-Tenorio G; Fornander T; Skoog L; Nordenskjöld B; Carstensen J; Stål O
    Eur J Cancer; 2013 Apr; 49(6):1196-204. PubMed ID: 23305873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression pattern of stromal cell-derived factor-1 chemokine in invasive breast cancer is correlated with estrogen receptor status and patient prognosis.
    Kobayashi T; Tsuda H; Moriya T; Yamasaki T; Kikuchi R; Ueda S; Omata J; Yamamoto J; Matsubara O
    Breast Cancer Res Treat; 2010 Oct; 123(3):733-45. PubMed ID: 20020198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers.
    Castellano I; Allia E; Accortanzo V; Vandone AM; Chiusa L; Arisio R; Durando A; Donadio M; Bussolati G; Coates AS; Viale G; Sapino A
    Breast Cancer Res Treat; 2010 Dec; 124(3):607-17. PubMed ID: 20127405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The reversal of recurrence hazard rate between ER positive and negative breast cancer patients with axillary lymph node dissection (pathological stage I-III) 3 years after surgery.
    Kiba T; Inamoto T; Nishimura T; Ueno M; Yanagihara K; Teramukai S; Kato H; Toi M; Fukushima M
    BMC Cancer; 2008 Nov; 8():323. PubMed ID: 18990247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strength of ER-positivity in relation to survival in ER-positive breast cancer treated by adjuvant tamoxifen as sole systemic therapy.
    Morgan DA; Refalo NA; Cheung KL
    Breast; 2011 Jun; 20(3):215-9. PubMed ID: 21159509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy.
    Lin YC; Chen SC; Chang HK; Hsueh S; Tsai CS; Lo YF; Hwang TL; Chen MF
    Jpn J Clin Oncol; 2005 Sep; 35(9):514-9. PubMed ID: 16199422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns and predictors of early recurrence in postmenopausal women with estrogen receptor-positive early breast cancer.
    Mansell J; Monypenny IJ; Skene AI; Abram P; Carpenter R; Gattuso JM; Wilson CR; Angerson WJ; Doughty JC
    Breast Cancer Res Treat; 2009 Sep; 117(1):91-8. PubMed ID: 19112615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer.
    Partin JF; Mamounas EP
    Ann Surg Oncol; 2011 Nov; 18(12):3399-406. PubMed ID: 21537874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triple-negative breast cancer: the impact of guideline-adherent adjuvant treatment on survival--a retrospective multi-centre cohort study.
    Schwentner L; Wolters R; Koretz K; Wischnewsky MB; Kreienberg R; Rottscholl R; Wöckel A
    Breast Cancer Res Treat; 2012 Apr; 132(3):1073-80. PubMed ID: 22205141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Higher expression of androgen receptor is a significant predictor for better endocrine-responsiveness in estrogen receptor-positive breast cancers.
    Park S; Park HS; Koo JS; Yang WI; Kim SI; Park BW
    Breast Cancer Res Treat; 2012 May; 133(1):311-20. PubMed ID: 22231421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
    Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
    Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of mammography screening attendance and detection mode in predicting breast cancer survival-is there added prognostic value?
    Biesheuvel C; Czene K; Orgeás CC; Hall P
    Cancer Epidemiol; 2011 Dec; 35(6):545-50. PubMed ID: 21470933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.